Literature DB >> 32145478

Unusual, neurological and severe dengue manifestations during the outbreak in Sri Lanka, 2017.

Mya Myat Ngwe Tun1, Rohitha Muthugala2, Takeshi Nabeshima3, Lakmali Rajamanthri2, Dulani Jayawardana2, Shanthi Attanayake2, Aung Min Soe3, Shyam Prakash Dumre4, Tsuyoshi Ando3, Daisuke Hayasaka3, Shingo Inoue3, Corazon C Buerano5, Kouichi Morita3.   

Abstract

BACKGROUND: Sri Lanka experienced its largest dengue outbreak in 2017 with more than 185,000 dengue cases including at least 250 fatalities.
OBJECTIVES: Our study aimed to characterize the clinical, immunological and virological features of confirmed dengue patients in Sri Lanka during the outbreak in 2017 when unusual manifestations of severe dengue were observed. STUDY
DESIGN: Sera from 295 patients who were admitted to Teaching Hospital Kandy, Kandy, Sri Lanka between March 2017- January 2018 were subjected to NS1 antigen, IgM and IgG ELISAs, virus isolation, conventional and real time RT-PCR and next generation sequencing.
RESULTS: Primary and secondary infections were detected in 48.5 % and 51.5 % of the study population, respectively. Two hundred twenty five DENV strains were isolated (219 DENV-2, one DENV-3, two DENV-4, two mixed infections of DENV-2 and -3 and one mixed infection of DENV-2 and -4). Unusual and severe manifestations such as encephalitis, encephalopathy, liver failure, kidney failure, myocarditis, Guillain-Barré syndrome and multi-organ failure were noted in 44 dengue patients with 11 deaths. The viraemia levels in patients with primary infection and unusual manifestations were significantly higher compared to those in patients with secondary infection. A new clade of DENV-2 Cosmopolitan genotype strains was observed with the strains closely related to those from China, Malaysia, Indonesia, Singapore and Taiwan.
CONCLUSIONS: The new clade of DENV-2 cosmopolitan genotype observed in Sri Lanka in 2017 caused an unprecedented, severe dengue outbreak. The emergence of DENV-3 and DENV-4 in the 2017 outbreak might cause future outbreaks in Sri Lanka.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Molecular epidemiology; Serology; Severe dengue; Sri Lanka; Unusual manifestations

Mesh:

Substances:

Year:  2020        PMID: 32145478     DOI: 10.1016/j.jcv.2020.104304

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

1.  Case Report: Dengue Hemorrhagic Fever with Ischemic Stroke.

Authors:  Basnayake Wasala Mudiyanselage Kumarini Eranthika Basnayake; Kaluachchi Gamage Samanthi Kumari Somaratne; Chathuri Udeshika Goonetilleke; Pattiniya Markkala Yasoma Indrani Tilakaratna; Udaya Kumara Ranawaka
Journal:  Am J Trop Med Hyg       Date:  2021-11-15       Impact factor: 2.345

2.  Acute-phase Serum Cytokine Levels and Correlation with Clinical Outcomes in Children and Adults with Primary and Secondary Dengue Virus Infection in Myanmar between 2017 and 2019.

Authors:  Khine Mya Nwe; Mya Myat Ngwe Tun; Theingi Win Myat; Chris Fook Sheng Ng; Moh Moh Htun; Htin Lin; Nang Sarm Hom; Aung Min Soe; Annie Elong Ngono; Shinjiro Hamano; Kouichi Morita; Kyaw Zin Thant; Sujan Shresta; Hlaing Myat Thu; Meng Ling Moi
Journal:  Pathogens       Date:  2022-05-09

Review 3.  Acute neurologic emerging flaviviruses.

Authors:  Marissa Caldwell; Abhilasha P Boruah; Kiran T Thakur
Journal:  Ther Adv Infect Dis       Date:  2022-06-13

4.  The interrelationship between meteorological parameters and leptospirosis incidence in Hambantota district, Sri Lanka 2008-2017 and practical implications.

Authors:  N D B Ehelepola; Kusalika Ariyaratne; D S Dissanayake
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

5.  An Outbreak of Dengue Virus Serotype 2 Cosmopolitan Genotype in Nepal, 2017.

Authors:  Mya Myat Ngwe Tun; Kishor Pandey; Takeshi Nabeshima; Aung Kyaw Kyaw; Mandira Adhikari; Sandra Kendra Raini; Shingo Inoue; Shyam Prakash Dumre; Basu Dev Pandey; Kouichi Morita
Journal:  Viruses       Date:  2021-07-24       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.